TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system[1].
TRPC6-IN-3 (compound 17; 1-10 mg/kg; p.o.; orally 12 h and 2 h before LPS challenge; LPS-induced mice) inhibits LPS-induced vascular leakage and inhibits accumulation of Broncho-Alveolar-Lavage protein (BALF protein) in a mouse model[1].
TRPC6-IN-3 (3 mg/kg; p.o.; daily, for 4 d; H1N1-induced mice) reduces H1N1-induced vascular leakage in a mouse model[1].
| Animal Model: | LPS-induced mice[1] |
| Dosage: | 1, 3, and 10 mg/kg |
| Administration: | Oral administration; orally 12 h and 2 h before LPS challenge |
| Result: | Reduced BALF protein concentration of 56 % at 3 mg/kg and 62 % at 10 mg/kg. |
| Animal Model: | H1N1-induced mice[1] |
| Dosage: | 3 mg/kg |
| Administration: | Oral administration; daily, for 4 days |
| Result: | Inhibited Evans blue extravasation from the blood to the BALF and reduced BALF Evans blue by 24 % at 3 mg/kg. |
[1]. Thierry B, et, al. Inhibitors of TRPC6 for treating respiratory conditions. WO2021209510.